Form 4: Enliven Therapeutics CEO Sells Shares

Enliven Therapeutics President and CEO Samuel Kintz sold 2,800 shares of common stock for $20.03 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Samuel Kintz, President and CEO of Enliven Therapeutics, Inc. (ELVN), reported a sale of common stock.
• The transaction involved 2,800 shares of Enliven Therapeutics common stock.
• The shares were sold at a price of $20.03 per share, totaling $56,084.
• The sale was executed on September 23, 2025.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kintz on November 15, 2024.
• Following this transaction, Mr. Kintz directly beneficially owns 919,092 shares of common stock.
• Additional shares are held indirectly by The Kintz & Egan Trust Dated March 30, 2019, for which Mr. Kintz serves as trustee.

Sentiment

Score: 5

Explanation: The sale of shares by the President and CEO, while a reduction in direct equity, was executed under a pre-arranged Rule 10b5-1 trading plan, which typically indicates a planned liquidity event rather than a reaction to new company developments. The amount sold is also a small fraction of the insider's total beneficial ownership.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to immediate company news.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces management's direct equity stake.

Risks

• Potential negative investor sentiment if the market interprets the insider sale as a lack of confidence, despite the 10b5-1 plan.

Future Outlook

This Form 4 filing reports a past transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing reports an individual insider transaction and does not provide information to analyze broader industry trends or competitor activities.

Related Party Transactions

• The Kintz & Egan Trust Dated March 30, 2019, holds shares indirectly for which the reporting person serves as trustee. This represents an indirect beneficial ownership by a related party.

Stakeholder Impact

• Shareholders: May interpret the insider sale, even if pre-planned, as a signal, though the small size and 10b5-1 plan mitigate significant negative implications.
• Employees, Customers, Suppliers, Creditors: Unlikely to be directly impacted by this specific insider transaction.

Key Dates

Keywords

Enliven Therapeutics, ELVN, Samuel Kintz, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Beneficial Ownership, CEO